Clinical Pharmacology & Mechanism of Action
TB-500 is a synthetic version of the active region of Thymosin Beta-4 (Tβ4), a naturally occurring peptide present in almost all animal and human cells, with the highest concentrations found in blood platelets, wound fluid, and other tissues. Its primary role in the body revolves around the regulation of actin - a cell-building protein essential for cellular mobility and structure.
By upregulating actin, TB-500 plays a crucial role in angiogenesis (blood vessel formation), tissue repair, and cell migration. It essentially acts as an architectural coordinator, commanding white blood cells to travel to the site of an injury and orchestrating the building of new tissue networks.
Unlike BPC-157 which heavily focuses on localized blood flow via VEGF, TB-500 modulates inflammation and downregulates inflammatory cytokines while providing systemic cellular protection .
Pharmacokinetics & Systemic Nature
TB-500 has a remarkably low molecular weight. This makes it highly mobile, allowing it to travel freely through tissues and the systemic circulatory system over long distances.
- Half-life: TB-500 has a relatively long half-life in the body compared to many other peptides (up to 7-10 days in some models). This dictates a significantly different dosing schedule than BPC-157.
- Systemic Efficacy: Because it is highly systemic, injecting it close to an injury site (e.g., injecting near a torn muscle) is rarely necessary. A standard subcutaneous injection in the abdomen will effectively deliver the peptide throughout the entire body to wherever inflammation or damage is present.
Standard Research Dosing Protocols
Because of its longer half-life, TB-500 is rarely injected daily. The standard clinical and experimental paradigm focuses on a "loading phase" followed by a "maintenance phase."
Loading Phase (Weeks 1-4 or 1-6)
- Dosage: 4.0mg to 10.0mg per week total.
- Frequency: Typically divided into two injections per week (e.g., 2.5mg on Monday and 2.5mg on Thursday).
Maintenance Phase (Weeks 6+)
- Dosage: 2.0mg to 5.0mg per month.
- Frequency: Usually administered as one 2.0mg injection every two weeks or once per month depending on the severity of the ongoing injury.
Reconstitution Math & Syringe Guide
A common mistake with TB-500 is assuming it must be mixed identically to BPC-157. While the math logic is the same, TB-500 research doses are much larger (milligrams rather than micrograms), which means you need a less concentrated solution to avoid injecting massive amounts of water.
Step-by-Step Reconstitution (5mg Vial)
- Swab the rubber stoppers of the 5mg TB-500 vial and the Bacteriostatic Water.
- Draw exactly 2mL of Bacteriostatic Water.
- Inject the water slowly down the glass wall of the TB-500 vial.
- Gently swirl until dissolved.
The Math for a 2.5mg Dose:
- 5mg total in the vial.
- You added 2mL of water.
- Therefore, the concentration is 2.5mg per 1mL.
- A standard U-100 insulin syringe holds 1mL (which equals 100 units).
- To get a 2.5mg dose, you draw a full 1.0mL.
- 1.0mL = 100 units (an entire U-100 syringe).
Note: If you have a 10mg vial of TB-500 and add 2mL of water, your concentration is 5mg/mL. A 2.5mg dose would then only require 50 units (0.5mL).
Common Mistakes & Troubleshooting
- Confusing it with BPC-157: Researchers often try to dose TB-500 at 250mcg twice daily because they run it alongside BPC-157. TB-500 requires milligram dosages spaced out over the week.
- Using a U-30 or U-50 Syringe: Because TB-500 doses often require drawing 0.5mL or 1.0mL of liquid, using small U-30 (0.3mL) syringes will force you to pin yourself multiple times for a single dose. Always use a 1mL (U-100) syringe.
- Lethargy: A small subset of researchers report feeling lethargic or tired the day after a large TB-500 injection. This is a known, though harmless, side effect of systemic inflammation modulation.